In vivo ocular fluorophotometry: Delivery of fluoresceinated dextrans via transscleral diffusion in rabbits

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 10, 2011, Pages 7038-7045

  Berezovsky, Damian E ^a   Patel, Samirkumar R ^b   McCarey, Bernard E ^a   Edelhauser, Henry F ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Georgia Institute of Technology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE DEXTRAN; FLUORESCEIN SODIUM;

ANIMAL EXPERIMENT; ARTICLE; CHOROID; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIFFUSION; FLUORESCENCE; FLUOROPHOTOMETRY; IN VIVO OCULAR FLUOROPHOTOMETRY; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RABBIT; RETINA; TRANSSCLERAL DIFFUSION; VITREOUS BODY;

ANIMALS; CHOROID; DEXTRANS; DIFFUSION; FLUORESCEIN; FLUORESCEIN-5-ISOTHIOCYANATE; FLUOROPHOTOMETRY; INJECTIONS, INTRAOCULAR; RABBITS; RETINA; SCLERA; TISSUE DISTRIBUTION; VITREOUS BODY;

EID: 80052495845     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-7207     Document Type: Article

References (30)

1. Michels S, Schmidt-Erfurth U, Rosenfeld PJ. Promising new treatments for neovascular age-related macular degeneration. Expert Opin Investig Drugs. 2006;15(7):779-793, 2006.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-1431.
3. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
4. Klein KS, Walsh MK, Hassan TS, et al. Endophthalmitis after anti-VEGF injections. Ophthalmology. 2009;116(6):1225, e1221.
5. Edelhauser HF, Rowe-Rendleman CL, Robinson MR, et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci. 2010;51(11):5403-5420.
6. Montero JA, Ruiz-Moreno JM. Intravitreal inserts of steroids to treat diabetic macular edema. Curr Diabetes Rev. 2009;5(1):26-32.
7. Kane FE, Burdan J, Cutino A, Green KE. Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv. 2008;5(9):1039-1046.
8. Bourges JL, Bloquel C, Thomas A, et al. Intraocular implants for extended drug delivery: therapeutic applications. Adv Drug Deliv Rev. 2006;58(11):1182-1202.
9. Lee SS, Ghosn C, Yu Z, et al. Vitreous VEGF clearance is increased aater vitrectomy. Invest Ophthalmol Vis Sci. 2010;51:2135-2138.
10. Olsen TW, Edelhauser HF, Lim JI, Geroski DH. Human scleral permeability: effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci. 1995;36(9): 1893-1903.
11. Ambati J, Canakis CS, Miller JW, et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci. 2000;41(5):1181-1185.
12. Robinson MR, Lee SS, Kim H, et al. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res. 2009;82(3):479-487.
13. Pitkanen L, Ranta VP, Moilanen H, Urtti A. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. Invest Ophthalmol Vis Sci. 2005;46(2):641-646.
14. Ghate D, Brooks W, McCarey BE, Edelhauser HF. Pharmacokinetics of intraocular drug delivery by periocular injections using ocular fluorophotometry. Invest Ophthalmol Vis Sci. 2007;48(5):2230-2237.
15. Blair NP, Zeimer RC, Rusin MM, Cunha-Vaz JG. Outward transport of fluorescein from the vitreous in normal human subjects. Arch Ophthalmol. 1983;101(7):1117-1121.
16. Raines MF. Vitreous fluorophotometry: a review. J R Soc Med. 1988;81(7):403-406.
17. Lee SJ, Kim ES, Geroski DH, McCarey BE, Edelhauser HF. Pharmacokinetics of intraocular drug delivery of Oregon green 488-labeled triamcinolone by subtenon injection using ocular fluorophotometry in rabbit eyes. Invest Ophthalmol Vis Sci. 2008; 49(10):4506-4514.
18. Wallace MB, Meining A, Canto MI, et al. The safety of intravenous fluorescein for confocal laser endomicroscopy in the gastrointestinal tract. Aliment Pharmacol Ther. 2010;31(5):548-552.
19. Das T, Vedantham V. Intravitreal sodium fluorescein enhances visualization of clear vitreous during vitreous surgery for macular hole: a safety and efficacy study. Clin Exp Ophthalmol. 2004;32(1):55-57.
20. Li SK, Lizak MJ, Jeong EK. MRI in ocular drug delivery. NMR Biomed. 2008;21(9):941-956.
21. Kim H, Robinson MR, Lizak MJ, et al. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest Ophthalmol Vis Sci. 2004; 45(8):2722-2731.
22. Zeimer RC, Cunha-Vaz JG, Johnson ME. Studies on the technique of vitreous fluorophotometry. Invest Ophthalmol Vis Sci. 1982; 22(5):668-674.
23. Klettner A, Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci. 2008;49(10):4523-4527.
24. Alm A, Nilsson SF. Uveoscleral outflow: a review. Exp Eye Res. 2009;88(4):760-768.
25. Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87(12):1479-1488.
26. Ranta VP, Urtti A. Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv Drug Deliv Rev. 2006;58(11):1164-1181.
27. Thale A, Tillmann B. The collagen architecture of the sclera: SEM and immunohistochemical studies. Ann Anat. 1993;175(3):215-220.
28. Pontes de Carvalho RA, Krausse ML, et al. Delivery from episcleral exoplants. Invest Ophthalmol Vis Sci. 2006;47(10):4532-4539.
29. Shen L, You Y, Sun S, Chen Y, Qu J, Cheng L. Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application. Ophthalmology. 2010; 117(12):2365-2371.
30. Cardillo JA, Melo LA Jr, Costa RA, et al. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology. 2005;112(9):1557-1563.